MA45660A - 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2 - Google Patents

3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2

Info

Publication number
MA45660A
MA45660A MA045660A MA45660A MA45660A MA 45660 A MA45660 A MA 45660A MA 045660 A MA045660 A MA 045660A MA 45660 A MA45660 A MA 45660A MA 45660 A MA45660 A MA 45660A
Authority
MA
Morocco
Prior art keywords
methylpyrazines
shp2
trisubstituted
disubstituted
allosteric inhibitors
Prior art date
Application number
MA045660A
Other languages
English (en)
Inventor
Naing Aay
Andreas Buckl
Adrian Gill
Ashutosh Jogalekar
Gert Kiss
Elena S Koltun
Kevin Mellem
Christopher Semko
Walter Won
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MA45660A publication Critical patent/MA45660A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/26—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MA045660A 2016-07-12 2017-07-11 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2 MA45660A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662361249P 2016-07-12 2016-07-12
US201762449523P 2017-01-23 2017-01-23

Publications (1)

Publication Number Publication Date
MA45660A true MA45660A (fr) 2019-05-22

Family

ID=59383648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045660A MA45660A (fr) 2016-07-12 2017-07-11 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu'inhibiteurs allostériques de shp2

Country Status (22)

Country Link
US (3) US10590090B2 (fr)
EP (2) EP3484856B1 (fr)
JP (3) JP6916279B2 (fr)
KR (2) KR102598895B1 (fr)
CN (3) CN116478131A (fr)
AU (3) AU2017296289A1 (fr)
CA (1) CA3030167A1 (fr)
CL (1) CL2019000090A1 (fr)
CO (1) CO2019000613A2 (fr)
CR (1) CR20190063A (fr)
DO (1) DOP2019000005A (fr)
EC (1) ECSP19010079A (fr)
IL (3) IL311645B2 (fr)
MA (1) MA45660A (fr)
MX (2) MX395351B (fr)
MY (1) MY199046A (fr)
PE (1) PE20190624A1 (fr)
PH (1) PH12019500056B1 (fr)
SG (1) SG11201900157RA (fr)
TN (1) TN2019000010A1 (fr)
TW (1) TWI806832B (fr)
WO (1) WO2018013597A1 (fr)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
AU2017274199B2 (en) 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
WO2018218133A1 (fr) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2
WO2019051084A1 (fr) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Compositions d'inhibiteur de la shp2 et méthodes de traitement du cancer
TW202517628A (zh) 2017-09-11 2025-05-01 美商克魯松藥物公司 Shp2之八氫環戊烷并[c]吡咯別構抑制劑
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
SG11202007740TA (en) 2018-02-13 2020-09-29 Shanghai Blueray Biopharma Co Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
BR112020019385A2 (pt) * 2018-03-21 2021-03-30 Relay Therapeutics, Inc. Inibidores de shp2 fosfatase e métodos de uso dos mesmos
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
WO2019183364A1 (fr) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase pyrazolo[3,4-b]pyrazine shp2 et leurs procédés d'utilisation
CA3096535A1 (fr) * 2018-04-10 2019-10-17 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 et methodes de traitement du cancer
MX2020011528A (es) * 2018-05-02 2021-02-09 Navire Pharma Inc Inhibidores heterociclicos sustituidos de ptpn11.
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
SG11202100199UA (en) 2018-08-10 2021-02-25 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
CN112996795B (zh) * 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
KR20210068472A (ko) * 2018-09-29 2021-06-09 노파르티스 아게 Shp2 활성의 억제를 위한 화합물 및 조성물의 제조
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020076723A1 (fr) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 destinées à être utilisées dans le traitement du cancer
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
MA53921A (fr) 2018-10-17 2022-01-26 Array Biopharma Inc Inhibiteurs de protéine tyrosine phosphatase
CN109265352B (zh) * 2018-10-31 2021-06-04 杭州迈世腾药物科技有限公司 芳基环丙基醚及其衍生物的制备方法
CA3120791A1 (fr) 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine et derive heterocycle pentagonal de nitrogene, leur procede de preparation et applications medicales
CN113316574B (zh) * 2019-01-31 2024-01-30 贝达药业股份有限公司 Shp2抑制剂及其应用
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
CA3127361A1 (fr) 2019-03-07 2020-09-10 Merck Patent Gmbh Derives de carboxamide-pyrimidine utilises en tant qu'antagonistes de shp2
BR112021018664A2 (pt) * 2019-04-02 2021-11-23 Array Biopharma Inc Inibidores de proteína tirosina fosfatase
US11001561B2 (en) 2019-04-08 2021-05-11 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
KR20220019017A (ko) * 2019-06-07 2022-02-15 레볼루션 메디슨즈, 인크. ｛6-[(2-아미노-3-클로로피리딘-4-일)설파닐]-3-[(3s,4s)-4-아미노-3-메틸-2-옥사-8-아자스피로[4.5]데칸-8-일]-5-메틸피라진-2-일｝메탄올의 고체 형태인 shp2 저해제
WO2020259679A1 (fr) 2019-06-28 2020-12-30 上海拓界生物医药科技有限公司 Dérivé hétérocyclique azoté à cinq chaînons de pyrimidine, son procédé de préparation et son utilisation pharmaceutique
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
CN112300160A (zh) * 2019-08-01 2021-02-02 上海奕拓医药科技有限责任公司 一种螺芳环化合物、其制备及应用
EP3772513A1 (fr) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Inhibiteurs d'shp2
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CN114127053B (zh) * 2019-09-06 2023-06-13 四川科伦博泰生物医药股份有限公司 一种取代吡嗪化合物、其制备方法和用途
WO2021061515A1 (fr) * 2019-09-23 2021-04-01 Synblia Therapeutics, Inc. Inhibiteurs de shp2 et leurs utilisations
WO2021061706A1 (fr) 2019-09-24 2021-04-01 Relay Therapeutics, Inc. Inhibiteurs de phosphatase shp2, procédés de production et d'utilisation associés
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
EP4045047A1 (fr) 2019-10-15 2022-08-24 Amgen Inc. Multithérapie d'inhibiteur de kras et d'inhibiteur de shp2 pour le traitement de cancers
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤
EP4054719B1 (fr) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Inhibiteurs de ras
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2021108683A1 (fr) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
WO2021110796A1 (fr) 2019-12-04 2021-06-10 Bayer Aktiengesellschaft Inhibiteurs de shp2
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
US20230348467A1 (en) 2020-01-16 2023-11-02 Zhejiang Hisun Pharmaceutical Co., Ltd. Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof
CN113135910A (zh) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
CN114846005B (zh) * 2020-01-21 2024-04-02 贝达药业股份有限公司 Shp2抑制剂及其应用
TW202146021A (zh) 2020-02-28 2021-12-16 瑞士商諾華公司 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
TW202144334A (zh) * 2020-04-03 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜芳類衍生物游離鹼的晶型
CN113493440B (zh) * 2020-04-03 2024-08-23 上海翰森生物医药科技有限公司 含氮杂芳类衍生物的盐及其晶型
WO2021218752A1 (fr) * 2020-04-26 2021-11-04 Betta Pharmaceuticals Co., Ltd Inhibiteurs de shp2, compositions et utilisations de ceux-ci
IL298917A (en) * 2020-06-11 2023-02-01 Betta Pharmaceuticals Co Ltd Shp2 inhibitors, compositions and uses thereof
CA3183032A1 (fr) 2020-06-18 2021-12-23 Mallika Singh Methodes de retardement, de prevention et de traitement de la resistance acquise aux inhibiteurs de ras
JP2023530838A (ja) 2020-06-22 2023-07-20 スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用
TW202216723A (zh) 2020-07-08 2022-05-01 瑞士商諾華公司 用於抑制shp2活性的化合物及組成物之製造
CN116113418A (zh) * 2020-08-25 2023-05-12 四川科伦博泰生物医药股份有限公司 杂环化合物及其制备方法和用途
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
UY39477A (es) 2020-10-20 2022-05-31 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso
US20230406860A1 (en) 2020-10-27 2023-12-21 Amgen Inc. Heterocyclic spiro compounds and methods of use
CN116848121A (zh) * 2020-12-18 2023-10-03 建新公司 制备shp2抑制剂的方法
MX2023007226A (es) * 2020-12-18 2023-06-27 Genzyme Corp Proceso de preparacion de inhibidores de shp2.
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CN116568308A (zh) * 2021-01-29 2023-08-08 四川科伦博泰生物医药股份有限公司 一类杂环类shp2抑制剂、其制备方法及用途
EP4039685A1 (fr) 2021-02-08 2022-08-10 Irbm S.P.A. Inhibiteurs azabicycliques de shp2
CN117083285A (zh) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 一系列含Se的吡嗪类化合物及其应用
KR20230165309A (ko) * 2021-04-01 2023-12-05 어레이 바이오파마 인크. Shp2 억제제의 결정질 형태
EP4067358A1 (fr) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine et composés similaires en tant qu'inhibiteurs de shp2 pour le traitement par ex. du cancer
JP2024517693A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド ２－アミノベンゾチアゾール化合物及びその使用方法
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
IL308222A (en) 2021-05-05 2024-01-01 Huyabio Int Llc Combination therapies that include SHP2 inhibitors and PD-1 inhibitors
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
JP2024516997A (ja) * 2021-05-05 2024-04-18 フヤバイオ インターナショナル，エルエルシー Ｓｈｐ２阻害剤単独療法およびその使用
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
EP4333847A1 (fr) 2021-05-05 2024-03-13 Novartis AG Composés et compositions pour le traitement d'une mpnst
JP7656087B2 (ja) * 2021-05-13 2025-04-02 中国科学院上海薬物研究所 Ｓｈｐ２活性を阻害する複素環化合物、その製造方法および使用
EP4342891A4 (fr) 2021-05-21 2025-05-14 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Composé spiro et son utilisation
WO2022259157A1 (fr) 2021-06-09 2022-12-15 Novartis Ag Combinaison pharmaceutique triple comprenant du dabrafenib, du trametinib et un inhibiteur de shp2
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
IL309984A (en) * 2021-07-09 2024-03-01 Kanaph Therapeutics Inc Shp2 inhibitor and use thereof
CN113636952B (zh) * 2021-07-19 2023-07-21 河南农业大学 一种制备4-溴苯甲酰胺的方法
KR20240050360A (ko) * 2021-08-09 2024-04-18 주식회사 유빅스테라퓨틱스 Shp2 단백질 분해활성을 갖는 화합물 및 이들의 의약 용도
TW202327569A (zh) 2021-09-01 2023-07-16 瑞士商諾華公司 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
CN116323566B (zh) * 2021-09-27 2024-05-17 中国医药研究开发中心有限公司 磺胺酮类化合物及其制备方法和医药用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250109118A1 (en) * 2021-12-28 2025-04-03 Js Innomed Holdings Ltd. Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CA3251671A1 (fr) 2022-02-16 2023-08-24 Amgen Inc. Composés quinazoline et leur utilisation en tant qu'inhibiteurs de protéines kras mutantes
EP4479401A1 (fr) 2022-02-16 2024-12-25 Amgen Inc. Composés de quinazoline et leur utilisation en tant qu'inhibiteurs de protéines kras mutantes
US20250177389A1 (en) 2022-03-04 2025-06-05 Eli Lilly And Company Method of treatment including kras g12c inhibitors and shp2 inhibitors
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023169170A1 (fr) * 2022-03-10 2023-09-14 捷思英达控股有限公司 Composé hétérocyclique utilisé en tant qu'inhibiteur de shp2, composition comprenant un composé hétérocyclique, et procédé l'utilisant
US20250134885A1 (en) 2022-03-21 2025-05-01 Institut National de la Santé et de la Recherche Médicale Use of shp2 inhibitors for inhibiting senescence
EP4499648A1 (fr) * 2022-03-28 2025-02-05 Genzyme Corporation Procédé de préparation d'inhibiteurs de shp2
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
WO2024015360A1 (fr) 2022-07-11 2024-01-18 Amgen Inc. Méthodes de traitement du cancer
WO2024040131A1 (fr) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Inhibiteurs de pyridopyrimidine kras
EP4345101A1 (fr) 2022-09-29 2024-04-03 Irbm S.P.A. Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2
EP4606799A1 (fr) * 2022-10-19 2025-08-27 Ubix Therapeutics, Inc. Composé pour la dégradation de la protéine shp2 et ses utilisations médicales
JP2025539080A (ja) 2022-11-14 2025-12-03 アムジエン・インコーポレーテツド 大環状ｋｒａｓ阻害剤及び使用方法
WO2024113194A1 (fr) * 2022-11-30 2024-06-06 Canwell Biotech Limited Inhibiteurs de shp2, compositions et procédés associés
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025064848A1 (fr) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Inhibiteurs de kras de type dihydropyranopyrimidines spirocycliques
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025081291A1 (fr) * 2023-10-16 2025-04-24 Canwell Biotech Limited Dérivés de benzo [c] [1, 2] oxaborol-1(3h)-ol utilisés comme inhibiteurs de shp2, compositions et méthodes associées
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025194057A1 (fr) 2024-03-14 2025-09-18 Amgen Inc. Composés macrocycliques utilisés en tant que modulateurs de kras et leurs utilisations
WO2025194054A1 (fr) 2024-03-14 2025-09-18 Amgen Inc. Composés spirocycliques utilisés en tant que modulateurs de kras et leurs utilisations
WO2025217247A1 (fr) 2024-04-10 2025-10-16 Amgen Inc. Inhibiteurs spiro-hétérocycliques ancrés de protéines mutantes kras g12c et leurs utilisations
WO2025230878A1 (fr) 2024-04-29 2025-11-06 Amgen Inc. Composés macrocycliques utilisés en tant que modulateurs de kras et leurs utilisations
WO2025240582A1 (fr) 2024-05-14 2025-11-20 Amgen Inc. Composés macrocycliques utilisés en tant que modulateurs de kras et leurs utilisations
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (fr) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Inhibiteurs de dihydropyranopyrimidine kras spirocycliques
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026055477A1 (fr) 2024-09-06 2026-03-12 Amgen Inc. Composés macrocycliques constituant des modulateurs de kras et leurs utilisations
CN119661551B (zh) * 2024-12-16 2025-11-25 重庆大学 一种(3r,4s)-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-4-胺盐酸盐的制备方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2572728A (en) * 1949-01-07 1951-10-23 American Cyanamid Co Hydroxybenzenesulfonamidopyra-zines and preparation of same
US2636882A (en) 1950-08-11 1953-04-28 Quaker Oats Co Preparation of 3-pyridols from 2-acylfurans
BE758503A (fr) 1969-11-07 1971-05-05 Shell Int Research Compositions pesticides
GB1459571A (en) 1974-09-12 1976-12-22 Pfizer Ltd Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
JPS5762269A (en) * 1980-10-03 1982-04-15 Ogawa Koryo Kk 2,3,5-trisubstituted pyrazine derivative
US4513135A (en) * 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
JPH0249775A (ja) 1988-05-19 1990-02-20 Nippon Soda Co Ltd ６員環又は７員環を有する複素環化合物及びその製造方法
JPH04112877A (ja) 1990-09-04 1992-04-14 Nippon Soda Co Ltd 新規シアノピラジン誘導体及びその製造方法
EP0579835A4 (en) 1991-11-12 1994-06-01 Nippon Soda Co Wavelength conversion material for agriculture
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
DE880523T1 (de) 1996-02-07 2002-07-04 Janssen Pharmaceutica N.V., Beerse Pyrazolopyrimidine als crf rezeptor-antagonisten
EP1007042A4 (fr) * 1997-06-13 2001-07-04 Sugen Inc Nouveaux composes heteroaryle pour la modulation de la transduction de signaux cellulaires associee aux enzymes proteine tyrosine
ATE309207T1 (de) 1999-08-27 2005-11-15 Sugen Inc Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
AP2002002620A0 (en) 2000-02-16 2002-09-30 Neurogen Corp Substituted arylpyrazines
TWI316055B (fr) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CA2495529C (fr) 2001-10-01 2009-05-19 Mount Sinai School Of Medicine Of New York University Gene du syndrome de noonan
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
AU2002343557A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
JP2005533014A (ja) 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
JP2006506350A (ja) 2002-09-12 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換１，４−ピラジン誘導体
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1625125A1 (fr) 2003-05-09 2006-02-15 Pharmacia & Upjohn Company LLC Composes utilises comme antagonistes du recepteur de type 1 de la corticoliberine (crf)
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2856684B1 (fr) 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
WO2005028480A2 (fr) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, et pyrazines et composes associes
JP2007508290A (ja) 2003-10-10 2007-04-05 ファイザー・プロダクツ・インク ＧＳＫ−３阻害剤としての置換２Ｈ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
EP1678160A1 (fr) * 2003-10-27 2006-07-12 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ce derive
DE102004015954A1 (de) * 2004-04-01 2005-11-10 Ina-Schaeffler Kg Umschlingungstrieb
CA2562126A1 (fr) 2004-04-01 2005-10-13 Astellas Pharma Inc. Derives de pyrazine et utilisation pharmaceutique de ceux-ci comme antagonistes de l'adenosine
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
AU2005322114A1 (en) 2004-12-23 2006-07-06 Mallinckrodt Llc Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
EP1871762A2 (fr) * 2005-04-18 2008-01-02 Neurogen Corporation Antagonistes cb1 heteroaryle substitue
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP3061834B1 (fr) 2005-10-21 2020-01-08 The Regents of the University of California Mutations du gene shp-2 dans des melanomes
CA2616147A1 (fr) * 2006-02-24 2007-09-20 Mallinckrodt Inc. Procede pour utiliser des agents optiques
US8987474B2 (en) 2006-04-07 2015-03-24 University Of South Florida Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
US20090325973A1 (en) 2006-04-28 2009-12-31 Watterson D Martin Formulations containing pyridazine compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
MX2008015747A (es) 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
JP2010520238A (ja) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド 統合された光活性低分子および統合された光活性低分子使用
PT2144909E (pt) 2007-04-06 2011-06-29 Novartis Ag [2,6]naftiridinas úteis como inibidores de proteínas quinases
WO2008138842A1 (fr) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines et triazolopyrazines pour le traitement de maladies dégénératives et inflammatoires des articulations
WO2008138843A1 (fr) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines et triazolopyrimidines utiles pour le traitement de maladies dégénératives et inflammatoires des articulations
WO2008156174A1 (fr) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. Composé de pyrazinamide
JP2010535769A (ja) 2007-08-09 2010-11-25 メルク・シャープ・エンド・ドーム・コーポレイション ピリジンカルボキサミドオレキシン受容体アンタゴニスト
WO2009025823A1 (fr) 2007-08-21 2009-02-26 Amgen Inc. Inhibiteurs de la phosphodiestérase 10
JP2010031249A (ja) * 2008-06-23 2010-02-12 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
US8703770B2 (en) 2008-10-30 2014-04-22 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
JP5590040B2 (ja) * 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
EP2565193B1 (fr) 2009-01-23 2014-03-19 Rigel Pharmaceuticals, Inc. Compositions et procédés d'inhibition de la voie JAK
WO2010121212A2 (fr) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Inhibiteurs d'échafaudage d'indoline shp-2 et procédé de traitement du cancer
WO2010141275A1 (fr) 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide antagonistes du récepteur de l'orexine
CA2771190C (fr) * 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser
US8163283B2 (en) 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
CA2789071C (fr) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Anticorps contre le csf-1r humain et leurs utilisations
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
GB201106829D0 (en) * 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2012149280A2 (fr) 2011-04-29 2012-11-01 Abbott Laboratories Nouveaux composés tricycliques
CN103181918B (zh) 2011-05-04 2014-10-29 厦门大学 脂肪酸类化合物在制备预防和治疗肝癌药物中的应用
US20150005311A1 (en) * 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
TWI532727B (zh) * 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物
EP2882746B1 (fr) 2012-08-07 2016-12-07 Merck Patent GmbH Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
SG11201502763VA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
KR102196374B1 (ko) 2012-11-29 2020-12-31 케모센트릭스, 인크. Cxcr7 길항제
US20150352131A1 (en) 2013-01-16 2015-12-10 Rhode Island Hospital Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
CA2900303A1 (fr) * 2013-02-07 2014-08-14 Merck Patent Gmbh Derives de quinoxaline substitues et leur utilisation a titre de modulateurs allosteriques positifs du mglur4
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
CA2902026C (fr) 2013-03-13 2023-08-29 Prothena Biosciences Limited Immunotherapie contre tau
CN103554038B (zh) 2013-06-19 2015-10-14 云南大学 多卤代苯腈喹唑啉酮化合物及其制备方法和用途
US10093646B2 (en) * 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
MY187540A (en) 2014-08-01 2021-09-28 Nuevolution As Compounds active towards bromodomains
EP3189038B1 (fr) * 2014-09-05 2022-11-23 Celgene Quanticel Research, Inc. Inhibiteurs de la déméthylase 1 spécifique de la lysine
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
US20170362305A1 (en) 2014-12-17 2017-12-21 Siemens Healthcare Diagnostics Inc. Sandwich assay design for small molecules
EA032416B1 (ru) 2014-12-23 2019-05-31 Новартис Аг Соединения триазолопиримидина и их применения
WO2016112295A1 (fr) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Composés participant à une liaison de coopérativité et leurs utilisations
US10112929B2 (en) * 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
ES2805232T3 (es) * 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310779B1 (fr) 2015-06-19 2019-05-08 Novartis AG Composés et compositions pour l'inhibition de l'activité de shp2
WO2017011618A1 (fr) 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Conjugué de nanoparticules ciblé et procédé d'administration conjointe d'arnic et de médicament
JP7411326B2 (ja) 2015-10-01 2024-01-11 ワープ ドライブ バイオ インコーポレイテッド タンパク質－タンパク質インターフェースを分析するための方法および試薬
US11008372B2 (en) 2015-11-07 2021-05-18 Board Of Regents, The University Of Texas System Targeting proteins for degradation
WO2017156397A1 (fr) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Inhibiteurs hétérocycliques de ptpn11
EA202092442A3 (ru) * 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
KR20240033100A (ko) 2017-04-05 2024-03-12 레볼루션 메디슨즈, 인크. 협동 결합에 참여하는 화합물 및 그의 용도
US20210285955A1 (en) 2017-04-05 2021-09-16 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces
WO2018218133A1 (fr) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2
WO2019051084A1 (fr) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Compositions d'inhibiteur de la shp2 et méthodes de traitement du cancer
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
CN110156786B (zh) 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
SG11202007740TA (en) 2018-02-13 2020-09-29 Shanghai Blueray Biopharma Co Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
CN112368272B (zh) 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
CA3096535A1 (fr) 2018-04-10 2019-10-17 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 et methodes de traitement du cancer
HRP20230488T1 (hr) 2018-05-01 2023-08-04 Revolution Medicines, Inc. C40-, C28- I C-32-VEZANI ANALOZI RAPAMICINA KAO INHIBITORI mTOR
MX2020011564A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina unidos a c26 como inhibidores de mtor.
CA3111980A1 (fr) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Polytherapies
CN112996795B (zh) 2018-09-18 2024-11-12 尼坎治疗公司 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
WO2020076723A1 (fr) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 destinées à être utilisées dans le traitement du cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
IL284210B2 (en) 2018-12-21 2025-05-01 Revolution Medicines Inc Compounds that participate in covalent bonds and their uses
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤

Also Published As

Publication number Publication date
US20240116878A1 (en) 2024-04-11
US12565476B2 (en) 2026-03-03
IL311645A (en) 2024-05-01
DOP2019000005A (es) 2019-05-15
US20190210977A1 (en) 2019-07-11
PH12019500056B1 (en) 2024-01-31
EP3484856B1 (fr) 2023-11-15
EP3484856A1 (fr) 2019-05-22
AU2023266357A1 (en) 2023-12-07
BR112019000494A2 (pt) 2019-04-24
PE20190624A1 (es) 2019-04-26
AU2021277664A1 (en) 2021-12-23
KR20190026893A (ko) 2019-03-13
MX2019000548A (es) 2019-10-30
WO2018013597A4 (fr) 2018-04-05
US11661401B2 (en) 2023-05-30
AU2021277664B2 (en) 2023-08-17
JP2024009957A (ja) 2024-01-23
IL264186B2 (en) 2024-08-01
WO2018013597A1 (fr) 2018-01-18
IL311645B2 (en) 2025-11-01
TW202413340A (zh) 2024-04-01
CL2019000090A1 (es) 2019-06-21
IL264186A (en) 2019-02-28
CA3030167A1 (fr) 2018-01-18
MY199046A (en) 2023-10-11
IL264186B1 (en) 2024-04-01
PH12019500056A1 (en) 2019-10-14
NZ749959A (en) 2024-12-20
EP4302834A2 (fr) 2024-01-10
IL311645B1 (en) 2025-07-01
CR20190063A (es) 2019-05-27
TN2019000010A1 (en) 2020-07-15
MX395351B (es) 2025-03-25
CN109983001B (zh) 2023-04-04
AU2017296289A1 (en) 2019-01-31
KR20230156174A (ko) 2023-11-13
NZ790185A (en) 2025-06-27
CN109983001A (zh) 2019-07-05
CN116478132A (zh) 2023-07-25
US20210101870A1 (en) 2021-04-08
KR102598895B1 (ko) 2023-11-07
JP6916279B2 (ja) 2021-08-11
US10590090B2 (en) 2020-03-17
IL321811A (en) 2025-08-01
JP2019527728A (ja) 2019-10-03
JP2021176870A (ja) 2021-11-11
CN116478131A (zh) 2023-07-25
TWI806832B (zh) 2023-07-01
TW201808931A (zh) 2018-03-16
CO2019000613A2 (es) 2019-02-19
ECSP19010079A (es) 2019-04-30
EP4302834A3 (fr) 2024-07-17
JP7416740B2 (ja) 2024-01-17
SG11201900157RA (en) 2019-02-27
KR102921163B1 (ko) 2026-02-03
MX2022007607A (es) 2022-07-19

Similar Documents

Publication Publication Date Title
MA45660A (fr) 3-méthylpyrazines 2,5-disubstituées et 3-méthyl pyrazines 2,5,6-trisubstitués en tant qu&#39;inhibiteurs allostériques de shp2
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
IL266214B (en) 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors
MA52486A (fr) Pyridazinones utilisés en tant qu&#39;inhibiteurs de parp7
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu&#39;inhibiteurs de kinase
MA47125A (fr) Dérivés de pyrazole en tant qu&#39;inhibiteurs de malt1
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu&#39;inhibiteurs de nlrp3
MA43169A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de pi3k-gamma
MA45244A (fr) Pyridines substituées utilisées en tant qu&#39;inhibiteurs de dnmt1
MA40774A (fr) Dérivés de diaryle-urée en tant qu&#39;inhibiteurs de kinase p38
MA46981A (fr) Dérivés de benzimidazole en tant qu&#39;inhibiteurs de bromodomaine
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu&#39; inhibiteurs de rock
EP3526328A4 (fr) Polythérapie pour l&#39;inhibition de c3
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu&#39;inhibiteurs de rho-kinase
EP3386981A4 (fr) Hétérocycles utiles en tant qu&#39;agents anticancereux
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu&#39;inhibiteurs d&#39;isocitrate déshydrogénase
MA51438A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de lsd1
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu&#39;inhibiteurs de la parg
MA54567A (fr) Pyridine et composés de pyridimine en tant qu&#39;inhibiteurs de pi3k-gamma
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu&#39;inhibiteurs de jak
MA46193A (fr) Inhibiteurs hétéroaryles de pad4
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu&#39;inhibiteurs de c5a
HUE042840T2 (hu) 5-[(Piperazin-1-il)-3-oxo-propil]-imidazolidin-2,4-dion-származékok mint csontartritisz kezelésére alkalmas ADAMTS inhibitorok
MA46878A (fr) Composés de benzodiazolium en tant qu&#39;inhibiteurs d&#39;enac